Human RCTPubMed ID: 31570645·2019

PIONEER 3: Oral Semaglutide with Combination Therapy in Type 2 Diabetes

Rosenstock J, Allison D, Birkenfeld AL, et al.

Diabetes Care, 2019 · n = 1864

Key finding

Oral semaglutide 14mg added to metformin reduced HbA1c by 1.5%, achieved 60% A1c <7% versus 27% with placebo, weight loss of 3.9kg.

Summary

Phase 3b trial evaluating oral semaglutide in combination with metformin and other antidiabetic agents.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT